相关实验视频

Updated: Jul 2, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

对于来自乳腺癌的中枢神经系统转移的capecitabine的活性

Mariana Carvalho Gouveia^1,2,3, Cassio Murilo Hidalgo Filho^1,2,4, Raquel Andrade Moreno^1,5

¹Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av Dr Arnaldo 251, Cerqueira Cesar, São Paulo 01246-000, Brazil.

Ecancermedicalscience

|February 28, 2024

概括

卡佩奇他在乳腺癌 (BC) 中枢神经系统 (CNS) 转移中显示出内活性. 然而,患者面临着不良预后,特别是三阴性乳腺癌 (TNBC),当先进疗法有限时.

科学领域:

在瘤学瘤学.
医学瘤学医学瘤学
神经瘤学是一种神经瘤学.

背景情况:

中枢神经系统 (CNS) 转移代表了乳腺癌 (BC) 管理的重大挑战.
关于capecitabine作为中枢神经系统转移的单一药物的疗效的数据有限.
评估capecitabine的内活性对于治疗策略至关重要.

研究的目的:

评估capecitabine在患有乳腺癌 (BC) 中枢神经系统 (CNS) 转移的患者的内疗效.
为了确定客观反应率 (ORR),疾病控制率 (DCR),无进展生存率 (PFS) 和总生存率 (OS) 在这个人群中治疗capecitabine.

主要方法:

从BC治疗capecitabine的中枢神经系统转移患者的回顾性队列研究.
终点包括内中枢神经系统客观反应率 (CNS-ORR),中枢神经系统疾病控制率 (CNS-DCR),中枢神经系统无进展生存率 (CNS-PFS) 和整体生存率 (OS).
根据乳腺癌亚型分层分析:激素受体阳性HER2-阴性 (HR + HER2-),HER2-阳性 (HER2+) 和三阴性乳腺癌 (TNBC).

主要成果:

分析了209名患者,41.6%的HR + HER2-,33.9%的HER2+和26.4%的TNBC.
在3个月后,可评估患者中,中枢神经系统-ORR为41.6%,中枢神经系统-DCR为81.2%.
三重阴性乳腺癌 (TNBC) 呈现出数量上较高的中枢神经系统-ORR (61%),但与其他亚型相比,中枢神经系统-PFS (3.0个月) 和OS (4.5个月) 显着较低.

结论:

凯普西塔在乳腺癌 (BC) 患者中表现出内活性,这些患者中枢神经系统转移.
患有中枢神经系统转移的患者无论BC亚型,预后都不好.
这些发现强调了需要有效的治疗选择,特别是对于TNBC,当先进的治疗方法无法使用时.

关键词:

中枢神经系统的转移.乳腺癌乳腺癌乳腺癌卡佩西塔宾 (capecitabine) 是一种药物.莱普托马尼格尔癌症 (leptomeningeal carcinomatosis) 是一种致癌的疾病.

更多相关视频

Ultrasound Imaging-guided Intracardiac Injection to Develop a Mouse Model of Breast Cancer Brain Metastases Followed by Longitudinal MRI

Ultrasound Imaging-guided Intracardiac Injection to Develop a Mouse Model of Breast Cancer Brain Metastases Followed by Longitudinal MRI

Published on: March 6, 2014

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...